Eli Lilly and Company (LLY)

NYSE: LLY · IEX Real-Time Price · USD
+29.16 (3.87%)
Mar 1, 2024, 3:59 PM EST - Market closed
Market Cap 743.14B
Revenue (ttm) 34.12B
Net Income (ttm) 5.24B
Shares Out 950.16M
EPS (ttm) 5.80
PE Ratio 134.97
Forward PE 61.78
Dividend $5.20 (0.66%)
Ex-Dividend Date Feb 14, 2024
Volume 3,789,730
Open 769.02
Previous Close 753.68
Day's Range 764.47 - 784.00
52-Week Range 309.32 - 794.47
Beta 0.32
Analysts Strong Buy
Price Target 671.82 (-14.18%)
Earnings Date Feb 6, 2024

About LLY

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the... [Read more]

Sector Healthcare
Founded 1876
Employees 43,000
Stock Exchange NYSE
Ticker Symbol LLY
Full Company Profile

Financial Performance

In 2023, LLY's revenue was $34.12 billion, an increase of 19.56% compared to the previous year's $28.54 billion. Earnings were $5.24 billion, a decrease of -16.08%.

Financial Statements

Analyst Forecast

According to 23 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $671.82, which is a decrease of -14.18% from the latest price.

Price Target
(-14.18% downside)
Analyst Consensus: Strong Buy
Stock Forecasts


3 Stocks Showing Constructive Pullbacks with Indexes at New Highs

One of the most exciting things for an investor or trader is to look at tier account statement, or at the charts of what they own, and see a stock like Nvidia Corp. NASDAQ: NVDA or even the broader SP...

Other symbols: ADBEMDB
2 days ago - MarketBeat

Eli Lilly and Novo Nordisk will remain leaders in the weight-loss drug market: Mizuho's Jared Holz

CNBC's Melissa Lee and Jared Holz, Mizuho Securities America healthcare sector strategist, join 'Squawk on Street' to discuss the weight-loss drug market, why he believes Eli Lilly and Novo Nordisk wi...

Other symbols: NVO
3 days ago - CNBC Television

Exclusive: Lilly CEO says its obesity drug could enter India as early as 2025

Eli Lilly 's CEO David Ricks told Reuters on Wednesday that the U.S. drugmaker expects to launch its obesity drug in Indian market as early as next year.

4 days ago - Reuters

More transparency in pharmaceuticals will be a tailwind for the space, says BMO's Evan Seigerman

Evan Seigerman, BMO biotech analyst, joins 'Power Lunch' to discuss the health care ecosystems in pharmaceuticals.

5 days ago - CNBC Television

Calls of the Day: Some bullish calls on Netflix, Eli Lilly, General Electric and Snowflake

The Investment Committee debates how to trade these names: Netflix, Eli Lilly, General Electric and Snowflake.

Other symbols: GENFLXSNOW
5 days ago - CNBC Television

Eli Lilly could be the next stock to cross $1 trillion, says Jim Cramer

'Mad Money' host Jim Cramer looks at the current class of $1 trillion stocks and looks at what stocks could be poised to join the group.

6 days ago - CNBC Television

Zealand's obesity drug shouldn't disrupt Novo Nordisk-Eli Lilly leadership: Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Fast Money' to talk obesity drugmakers after a new study out of Zealand Pharma analyzed the impact of GLP-1s on liver disease.

Other symbols: NVO
6 days ago - CNBC Television

Cramer names contenders for the next company to hit $1 trillion market cap

CNBC's Jim Cramer on Monday Eli Lilly, Berkshire Hathaway, Tesla and Broadcom have a chance to break the $1 trillion market cap barrier.

Other symbols: AVGOTSLA
6 days ago - CNBC

Novo Nordisk and Eli Lilly rival soars 26% after promising weight-loss drug results

Zealand Pharma's Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity, analysts said.

Other symbols: NVO
6 days ago - CNBC

3-Stock Lunch: AMZN, WBA & LLY

Boris Schlossberg, BK Asset Management managing director of FX Strategy, joins 'Power Lunch' to discuss stock plays for three stocks including; Amazon.com, Walgreens and Eli Lilly.

Other symbols: AMZNWBA
11 days ago - CNBC Television

Lilly to Participate in Cowen's 44th Annual Health Care Conference

INDIANAPOLIS , Feb. 20, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Cowen's 44th Annual Health Care Conference on March 6, 2024. Anat Ashkenazi, executive vice president...

12 days ago - PRNewsWire

EU drug regulator to review Lilly's Mounjaro in multi-dose pen

The European Union's healthcare regulator will this week review the use of Eli Lilly's approved Mounjaro drug against diabetes and obesity when prefilled in a multi-dose injection pen, according to a ...

13 days ago - Reuters

Why Eli Lilly is a top pick to capitalize on GLP-1 drug craze

As the craze surrounding weight loss drugs like GLP-1s continues, many investors are wondering how to capitalize on the massive valuation given to this sector by many on Wall Street. Matt Higgins, RSE...

16 days ago - Yahoo Finance

Calls of the Day: Trade Desk, Eli Lilly and Palo Alto Networks

The “Halftime Report” Investment Committee debate the biggest analyst calls of the day.

Other symbols: PANWTTD
16 days ago - CNBC Television

Eli Lilly, Novo Nordisk get growth stock status on weight-loss drug boost

U.S.-based Eli Lilly and Denmark's Novo Nordisk have struck gold with their weight-loss drugs, sending their shares to stratospheric levels and putting them on par with some high-growth tech stocks.

Other symbols: NVO
16 days ago - Reuters

Eli Lilly Stock's Upside Prompts Morgan Stanley to Ask if It Can Reach $1 Trillion

Morgan Stanley analyst Terence Flynn increases his price target on shares of the drugmaker to $950 from $805.

16 days ago - Barrons

Tiger Global slashes stakes in Magnificent Seven while piling into semiconductor makers

Tiger Global has slashed its positions in four of the five Magnificent Seven tech stocks that account for almost half of its portfolio, while upping its stake in Amazon.com and piling into semiconduct...

17 days ago - Market Watch

Chart Master: Charting four 'unstoppable' stocks

Carter Worth, Worth Charting, joins 'Fast Money' to talk four stocks he says are 'unstoppable' right now: Eli Lilly, Nvidia, Abercrombie and Fitch and Deckers Outdoor.

Other symbols: ANFDECKNVDA
18 days ago - CNBC Television

Britain sees launch of Lilly's weight-loss drug Mounjaro

Eli Lilly's Mounjaro drug is being launched in Britain this week, two pharmacy companies said on Wednesday, making the UK the fourth European country to introduce the highly-anticipated obesity drug.

18 days ago - Reuters

Eli Lilly's weight-loss drug could be the best selling drug of all time, says Jim Cramer

'Mad Money' host Jim Cramer looks at the top performing stocks on the S&P 500 as it reached the 5,000 milestone.

19 days ago - CNBC Television

Call of the Day: Eli Lilly getting a price target boost at Jefferies

Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to to discuss the latest raise to Eli Lilly.

19 days ago - CNBC Television

Eli Lilly partner BioAge raises $170 mln for obesity treatment

BioAge Labs, a biotech startup collaborating with Eli Lilly for trialing its obesity therapy, said on Tuesday it had raised $170 million in its latest funding round.

19 days ago - Reuters

Short sellers boosted by ‘Hedge Fund Nirvana' that sees most heavily-shorted companies suffer

Hedge funds with long/short strategies have benefited in 2024 from a macroeconomic environment that has hit the most heavily shorted stocks particularly hard compared to their less shorted rivals, a n...

20 days ago - Market Watch

Lilly Pulitzer CEO talks cost pressures, innovation, new products areas including home and athletic

The most recent University of Michigan Consumer Sentiment Index reading showed a climb in consumer sentiment despite dealing with sticky inflation (prices have not adjusted as quickly to supply and de...

22 days ago - Yahoo Finance

Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that

Novo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize on the success of their drugs.

Other symbols: NVO
22 days ago - CNBC